DICE Therapeutics, Inc.
DICE Therapeutics, Inc. (DICE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · DICE · as of Dec 31, 2021
Ownership Breakdown
69
Institutional Holders
▲ 30 vs Q3
$799.35M
Total Inst. Value
▲ $5.71M vs Q3
47.76M
Shares Outstanding
freeFloat 0.00%
31.68M
13F Shares Held
▲ 7.31M vs Q3
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
DICE largest shareholders · institutional ownership
Q4 2021 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 5.21M | 14.02% | 14.02% | $131.84B | Feb 14, 2022 | — held |
NORTHPOND VENTURES, LLC pharmaceutical preparations | 3.29M | 8.86% | 8.86% | $83.34B | Feb 15, 2022 | NEW |
SANDS CAPITAL VENTURES, LLC pharmaceutical preparations | 3.15M | 8.47% | 8.47% | $79.70B | Jan 21, 2022 | — held |
DRIEHAUS CAPITAL MANAGEMENT LLC pharmaceutical preparations | 2.15M | 5.78% | 5.78% | $54.33B | Feb 14, 2022 | ▲ 93.2K |
EVENTIDE ASSET MANAGEMENT, LLC pharmaceutical preparations | 1.87M | 5.04% | 5.04% | $45.76B | Feb 14, 2022 | — held |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 1.84M | 4.95% | 4.95% | $45.61B | Feb 14, 2022 | ▼ 25.0K |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 1.75M | 4.72% | 4.72% | $44.36B | Feb 14, 2022 | ▲ 250.5K |
LOGOS GLOBAL MANAGEMENT LP pharmaceutical preparations | 1.66M | 4.48% | 4.48% | $42.12B | Feb 14, 2022 | ▲ 504.0K |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 1.34M | 3.61% | 3.61% | $33.94B | Feb 14, 2022 | NEW |
BLACKROCK INC. pharmaceutical preparations | 855.3K | 2.30% | 2.30% | $21.65B | Feb 10, 2022 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q4 2021 vs prior quarter
Q4 2021
8
Increased
+1.01M shares22
New Positions
first time holders10
Decreased
−1.50M shares0
Sold Out
fully exitedNet shares change (top 50)
487.0K
+1.01M / −1.50M
Net new holders
+20
22 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
DICE insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
38
Sell transactions
0.00
Buy/Sell ratio
$4M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. | Aug 9, 2023 | D-Return | 21,250 | $14.98 | $318.3K | 0 | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P. | Aug 9, 2023 | U-Tender | 786,407 | $0.00 | $78.641 | 0 | Form 4 ↗ |
TETLOW SHARON director | Aug 9, 2023 | D-Return | 21,250 | $14.98 | $318.3K | 0 | Form 4 ↗ |
TETLOW SHARON director | Aug 9, 2023 | D-Return | 49,841 | $0.00 | $4.984 | 0 | Form 4 ↗ |
TETLOW SHARON director | Aug 9, 2023 | D-Return | 13,800 | $17.00 | $234.6K | 0 | Form 4 ↗ |
Simson Jake director | Aug 9, 2023 | D-Return | 21,250 | $14.98 | $318.3K | 0 | Form 4 ↗ |
Scopa James Paul director | Aug 9, 2023 | D-Return | 13,800 | $17.00 | $234.6K | 0 | Form 4 ↗ |
Scopa James Paul director | Aug 9, 2023 | D-Return | 21,250 | $14.98 | $318.3K | 0 | Form 4 ↗ |
Scopa James Paul director | Aug 9, 2023 | D-Return | 25,722 | $0.00 | $2.572 | 0 | Form 4 ↗ |
Robertson Scott M. CFO & CBO | Aug 9, 2023 | D-Return | 56,920 | $17.00 | $967.6K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
DICE Therapeutics, Inc. (DICE) is primarily owned by institutional investors, who hold approximately 66.3% of total shares outstanding. Company insiders own approximately 100.00%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of DICE Therapeutics, Inc. is RA CAPITAL MANAGEMENT, L.P., holding approximately 5.21 million shares — equal to 14.02% of outstanding shares — as of December 31, 2021.
A total of 69 institutional investors currently hold DICE stock, with a combined institutional value of approximately $799,351,488 as of the most recent 13F filing period.
Frequently asked questions
DICE ownershipDICE Therapeutics, Inc. (DICE) is primarily owned by institutional investors, who hold approximately 66.3% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 14.02% stake. Company insiders hold 100.00%. Data sourced from SEC Form 13F as of December 31, 2021.